Tumor selective miRNome modulation upon SAHA treatment in hepatocellular carcinoma

Epigenetic aberrations, including histone hypoacetylation, substantially contribute to initiation and progression of hepatocellular carcinoma (HCC). Newly developed drugs targeting epigenetic regulatory mechanisms, such as histone deacetylase inhibitors (HDACi), are available to reverse this contribution to the malignant phenotype of cancer cells. As a disease model in HCC e.g. the HDACi suberoylanilide hydroxamic acid (SAHA, VorinostatTM) was able to efficiently induce cell death in vitro and in vivo. Recently, microRNAs have been recognized to play an important role in tumor biology. In HCC several studies cle…